medigraphic.com

2008, Número 4

<< Anterior Siguiente >>

Arch Cardiol Mex 2008; 78 (4)


Manifestaciones cardiovasculares en el lupus eritematoso generalizado

Gómez-León MA, Amezcua-Guerra LM

Idioma: Español
Referencias bibliográficas: 80
Paginas: 421-430
Archivo PDF: 125.33 Kb.


RESUMEN

La pericarditis es la manifestación cardíaca más frecuente en pacientes con LEG, aunque las lesiones valvulares y la afección miocárdica y vascular pueden ocurrir. En el pasado, las manifestaciones cardíacas eran graves y ponían en riesgo la vida. Sin embargo, las opciones terapéuticas actuales han hecho que estas manifestaciones ahora sean frecuentemente asintomáticas y de bajo riesgo. Las oclusiones vasculares (incluyendo a las arterias coronarias) pueden ser condicionadas por aterosclerosis prematura, arteritis o por la frecuente asociación del LEG con el síndrome de anticuerpos antifosfolípidos. La aterosclerosis prematura es la causa más frecuente de enfermedad arterial coronaria en pacientes con LEG. Las terapias actuales permiten controlar la mayor parte de eventos de actividad lúpica; sin embargo, predisponen al desarrollo de un abanico de manifestaciones clínicas que presupone un nuevo reto diagnóstico y terapéutico para el clínico moderno.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Osler W: On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci 1904; 127: 1-17.

  2. Libman E, Sacks B: A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924; 33: 701-709.

  3. Kao AH, Manzi S: How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 2002; 16: 211-227.

  4. Kasitanon N, Magder LS, Petri M: Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006; 85: 147-156.

  5. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-706.

  6. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M: Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683-686.

  7. Bidani AK, Roberts JL, Schwartz MM, Lewis EJ: Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980; 69: 849-858.

  8. Kahl LE: The spectrum of pericardial tamponade in systemic lupus erythematosus: report of ten patients. Arthritis Rheum 1992; 35: 1343-1349.

  9. Sánchez-Guerrero J, Alarcón-Segovia D: Salmonella pericarditis with tamponade in systemic lupus erythematosus. Br J Rheumatol 1990; 29: 69-71.

  10. Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975; 58: 243-264.

  11. Roberts WC, High ST: The heart in systemic lupus erythematosus. Curr Probl Cardiol 1999; 24: 1-56.

  12. Doherty NE, Feldman G, Maurer G, Siegel RJ: Echocardiographic findings in systemic lupus erythematosus. Am J Cardiol 1988; 61: 1144.

  13. Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH: Cardiac abnormalities in systemic lupus erythematosus: a prospective M-mode, cross sectional and Doppler echocardiographic study. Int J Cardiol 1990; 27: 367-375.

  14. Cujec B, Sibley J, Haga M: Cardiac abnormalities in patients with systemic lupus erythematosus. Can J Cardiol 1991; 7: 343-349.

  15. Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A, et al: Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 1992; 51: 156-159.

  16. Giunta A, Picillo U, Maione S, Migliaresi S, Valentini G, Arnese M, et al: Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol 1993; 48: 183-197.

  17. Kalke S, Balakrishanan C, Mangat G, Mittal G, Kumar N, Joshi VR: Echocardiography in systemic lupus erythematosus. Lupus 1998; 7: 540-544.

  18. Gazarian M, Feldman BM, Benson LN, Gilday DL, Laxer RM, Silverman ED: Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr 1998; 132: 109-116.

  19. Berg G, Bodet J, Webb K, Williams G, Palmer D, Ruoff B, et al: Systemic lupus erythematosus presenting as isolated congestive heart failure. J Rheumatol 1985; 12: 1182-1185.

  20. Holmes D, St. Pierre M, Talley JD: Systemic lupus erythematosus: a review of the cardiac manifestations. J Ark Med Soc 1999; 95: 355-357.

  21. Petri M: Systemic lupus erythematosus and the cardiovascular system: the heart. En: Lahita RG, ed, Systemic lupus erythematosus. San Diego CA: Academic Press. 1999: 687-706.

  22. Moder KG, Miller TD, Tazelaar HD: Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74: 275-284.

  23. MacLean C, Brahn E: Systemic lupus erythematosus: calciphylaxis induced cardiomyopathy. J Rheumatol 1995; 22: 177-179.

  24. Falcao CA, Lucera N, Alves IC, Pessoa AL, Godoy ET: Lupus carditis. Arq Bras Cardiol 2000; 74: 55-71.

  25. Taniguchi I: Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern Med 2005; 44: 89-90.

  26. Logar D, Kveder T, Rozman B, Dobovisek J: Possible association between Ro-antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 627-629.

  27. O’Neill TW, Mahmoud A, Tooke A, Thomas RD, Maddison PJ: Is there a relationship between subclinical myocardial abnormalities, conduction defects and Ro/La antibodies in adults with systemic lupus erythematosus? Clin Exp Rheumatol 1993; 11: 409-412.

  28. Sandrasegaran K, Clarke CW, Nagendran V: Sub-clinical systemic lupus erythematosus presenting with acute myocarditis. Postgrad Med J 1992; 68: 475-478.

  29. Frustaci A, Gentiloni N, Caldarulo M: Acute myocarditis and left ventricular aneurysm as presentation of systemic lupus erythematosus. Chest 1996; 109: 282-284.

  30. Cheng SM, Chang DM, Lee WH, Ding YA: Acute myocarditis as an initial manifestation of systemic lupus erythematosus: a case report. Zhonghua Yi Xue Za Zhi 1996; 58: 205-208.

  31. Feldman AM, McNamara D: Myocarditis. N Engl J Med 2000; 343: 1388-1398.

  32. Fairfax MJ, Osborn TG, Williams GA, Tsai CC, Moore TL: Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 1988; 15: 593-596.

  33. Law WG, Thong BY, Lian TY, Kong KO, Chang HH: Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus 2005; 14: 827-831.

  34. Lagana B, Schillaci O, Tubani L, Gentile R, Danieli R, Coviello R, et al: Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology 1999; 50: 143-148.

  35. Schillaci O, Lagana B, Danieli R, Gentile R, Tubani L, Baratta L, et al: Technetium 99-m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 1999; 26: 713-717.

  36. Ishida R, Murata Y, Sawada Y, Nishioka K, Shibuya H: Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000; 21: 729-734.

  37. Singh JA, Woodard PK, Dávila-Román VG, Waggoner AD, Gutierrez FR, Zheng J, et al: Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus 2005; 14: 137-144.

  38. Omdal R, Lunde P, Rasmussen K, Mellgren SI, Husby G: Transesophageal and transthoracic echocardiography and Doppler-examination in systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 275-81.

  39. Roldan CA, Shively BK, Crawford MH: An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335: 1424-1430.

  40. Leszczynski P, Straburzynska-Migaj E, Korczowska I, Lacki JK, Mackiewicz S: Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol 2003; 22: 405-408.

  41. Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC: Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow up study. J Rheumatol 2004; 31: 2402-2407.

  42. Shahin AA, Shahin HA, Hamid MA, Amin MA: Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SSA and anti-La/SSB antibody levels. Mod Rheumatol 2004; 14: 117-122.

  43. Georghiou GP, Shapira Y, Drozd T, Erez E, Raanani E, Vidne BA, et al: Double-valve Libman-Sacks endocarditis: an entity that demands special consideration. J Heart Valve Dis 2003; 12: 797-801.

  44. Bharati S, de la Fuente DJ, Kallen RJ, Freij Y, Lev M: Conduction system in systemic lupus erythematosus with atrioventricular block. Am J Cardiol 1975; 35: 299-304.

  45. Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF et al: A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612-617.

  46. Costedot-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lchat P, Funck-Brentano C, et al: Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxicloroquine for connective tissue diseases. Rheumatology 2007; 46: 808-810.

  47. Lockshin MD, Bonfa E, Elkon K, Druzin ML: Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 697-701.

  48. Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, et al: Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 2002; 11: 716-721.

  49. Buyon JP, Ben-Chetrit E, Karp S, Roubey RA, Pompeo L, Reeves WH, et al: Acquired congenital heart block: pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest 1989; 84: 627-634.

  50. Hackel DB: Pathology of primary congenital complete heart block. Mod Pathol 1988; 1: 114-128.

  51. Ishibashi-Ueda H, Yutani C, Imakita M, Kanzaki T, Utsu M, Chiba Y: An autopsy case of congenital complete heart block in a newly born of a mother with systemic lupus erythematosus. Pediatr Cardiol 1988; 9: 157-161.

  52. Reed JH, Neufing PJ, Jackson MW, Clancy RM, Macardle PJBuyon JP, et al: Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol 2007; 148: 153-160.

  53. Clancy RM, Neufing PJ, Zheng P, O’Mahony M, Nimmerjahn F, Gordon TP, et al: Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and –SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116: 2413-2422.

  54. Costedoat-Chalmeau N, Amoura Z, Villain E, Cohen L, Piette JC: Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther 2005; 7: 69-73.

  55. Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, Wechsler B, Vauthier D, Ghillani P, et al: Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62: 1010-1012.

  56. Buyon JP, Clancy RM: Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. Semin Arthritis Rheum 2003; 33: 140-154.

  57. Johnsson H, Nived O, Sturfelt G: Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68: 141-150.

  58. Manzi S, Meilahn EM, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-415.

  59. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.

  60. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.

  61. Bruce IN, Urowitz MB, Gladman DD, Hallet DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-2143.

  62. Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-346.

  63. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J: Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-1264.

  64. Bruce IN, Burns RJ, Gladman DD, Urowitz MB: Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000; 27: 2372-2377.

  65. Roman MJ, Shanker BA, Davis A, Lockshin MD, Samaritano L, Simantov R et al: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.

  66. Ahmad Y, Bodill H, Shelmerdine J: Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Arthritis Rheum 2004; 50(Suppl 1): S191.

  67. Badui E, Garcia-Rubi D, Robles E, Jiménez J, Juan L, Deleze M, et al: Cardiovascular manifestations in systemic lupus erythematosus: prospective study of 100 patients. Angiology 1985; 36: 431-441.

  68. Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S: Cardiovascular disease in systemic lupus erythematosus: a study of 75 patients from a defined population. Medicine 1992; 71: 216-223.

  69. Hayder YS, Roberts WC: Coronary arterial disease in systemic lupus erythematosus: quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981; 70: 775-781.

  70. Bruce IN. “Not only… but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005; 44: 1492-1502.

  71. Korbet SM, Schwartz MM, Lewis EJ: Immune complex deposition and coronary vasculitis in systemic lupus erythematosus: report of two cases. Am J Med 1984; 77: 141-146.

  72. Wilson VE, Eck SL, Bates ER: Evaluation and treatment of acute myocardial infarction complicating systemic lupus erythematosus. Chest 1992; 101: 420-424.

  73. Sumino H, Kanda T, Sasaki T, Kanazawa N, Takeuchi H: Myocardial infarction secondary to coronary aneurysm in systemic lupus erythematosus: an autopsy case. Angiology 1995; 46: 527-530.

  74. Srock K, Kerr LD, Poon M, Fallon JT: Refractory pulmonary hypertension in a lupus patient with occult pulmonary vasculitis. J Clin Rheumatol 2003; 9: 263-266.

  75. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y: Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007; 6: 379-386.

  76. González-López L, Cardona-Muñoz EG, Celis A, García-de la Torre I, Orozco-Barocio G, Salazar-Páramo M, et al: Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105-112.

  77. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M: Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.

  78. Galie N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L, et al: Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005; 14: 713-717.

  79. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, et al: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002; 30: 2489-2492.

  80. Molina J, Lucero E, Luluaga S, Bellomio V, Spindler A, Berman A: Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 2003; 12: 321-323.




2020     |     www.medigraphic.com